Loss/deletions of 7q are associated with myelodysplastic syndromes (MDS), chronic myeloproliferative neoplasms, particularly idiopathic myelofibrosis (IMF) and acute myeloid leukemia (AML).  They are also frequent abnormalities in therapy-related MDS and AML, following previous exposure to alkylating agents. According to current NCCN AML guidelines, a -7 result is classified as a poor/adverse cytogenetic risk factor.  In MDS, a -7/ 7q- result is classified as a poor cytogenetic risk factor.  In MPN -7/7q- is classified as an unfavorable cytogenetic risk factor. 

This test can be ordered individually or as part of the AML or MDS FISH Panels. See these panel tests for more details

Bone marrow aspirate:

Collect bone marrow aspirate in a sterile Sodium heparin (Na hep) syringe and transfer to a sterile vial/tube

- or -

1. Collect bone marrow in sterile syringe (non-heparinized) and transfer to a Dk green Sodium heparin (Na hep), no gel
2. Immediately following collection, mix sample thoroughly by gently inverting 8 - 10 times, to prevent clotting

Transfer aspirate from syringe to transport container. 

Submit entire specimen unspun.

Sterile vial/tube

or

Dk green Sodium heparin (Na hep), no gel

Bone Marrow Core:

Submit in sterile tube/cup filled with sterile culture medium, sterile Hanks Balance Salt Solution (HBSS) or sterile saline

or 

Whole blood:

Dk green Sodium heparin (Na hep), no gel

Immediately following collection, mix sample thoroughly by gently inverting 8 - 10 times to prevent clotting.

Submit entire specimen unspun.

Sterile tube/cup

or

Dk green Sodium heparin (Na hepl), no gel

AHL Cytogenetics Oncology Request

Ambient

• Improper label (unlabeled or mislabeled)
• Wrong container (anticoagulant or solution)
• Delay in transport
• Improper storage
• Leaking container
• Slides broken beyond repair

Fluorescence in situ hybridization (FISH)

Normal or Abnormal with interpretation.

Medical necessity